Table 4.
Difference in adverse events associated with LEN between the <71 years and ≥ 71 years groups.
| Characteristic | All Patients | Age < 71 | Age ≥ 71 | p |
|---|---|---|---|---|
| n | 177 | 70 | 107 | |
| Hypertension (Presence/Absence) | 94 (53.1%) | 34/36 (48.6%/51.4%) |
60/47 (56.0%/44.0%) |
0.32 |
| Appetite loss (Presence/Absence) | 93 (52.5%) | 29/41 (41.4%/58.6%) |
64/43 (59.8%/40.2%) |
0.01 |
| Fatigue (Presence/Absence) |
90 (50.8%) | 35/35 (50.0%/50.0%) |
55/52 (51.4%/48.6%) |
0.86 |
| Hypothyroidism (Presence/Absence) | 86 (48.6%) | 31/39 (44.3%/55.7%) |
55/52 (51.4%/48.6%) |
0.35 |
| Proteinuria (Presence/Absence) |
67 (37.9%) | 19/51 (27.1%/72.9%) |
48/59 (44.9%/55.1%) |
0.01 |
| HFSR (Presence/Absence) |
50 (28.2%) | 25/45 (35.7%/64.3%) |
25/82 (23.4%/76.6%) |
0.08 |
| Diarrhea (Presence/Absence) | 34 (19.2%) | 14/56 (20.0%/80.0%) |
20/87 (18.7%/81.3%) |
0.82 |
| Appetite loss grade ≥2 (Presence/Absence) | 53 (30.8%) | 14/56 (20.0%/80.0%) |
39/68 (36.4%/63.6%) |
0.01 |
| Fatigue grade ≥3 (Presence/Absence) | 20 (11.3%) | 4/66 (5.7%/94.3%) |
16/91 (14.9%/84.1%) |
0.04 |
Abbreviations: LEN, lenvatinib; HFSR, hand-foot-skin-reaction.